Stephen D. Allen
Directeur/Membre du Conseil chez NTP Nano Tech Projects SRL
Profil
Stephen D.
Allen is currently the Director at NTP Nano Tech Projects SRL since 2023.
He was previously the Chief Executive Officer & Director at DNAe Group Holdings Ltd.
He also held director positions at Solexa Ltd.
from 2004 to 2009, Solexa, Inc. from 2005 to 2007, and Direct Conversion AB.
Prior to that, he was the Head-Automated Chemistry at Mettler-Toledo International, Inc. from 2000 to 2004 and Vice President-Product Development at PE Corp.
(New York) from 1999 to 2000.
Dr. Allen holds a doctorate degree from The University of Nottingham.
Postes actifs de Stephen D. Allen
| Sociétés | Poste | Début |
|---|---|---|
NTP Nano Tech Projects SRL
 NTP Nano Tech Projects SRL Miscellaneous Commercial ServicesCommercial Services NTP Nano Tech Projects SRL develops Nano-Eye, an advanced optical-laser microscopy device that can achieve optical resolutions below the micron size. The company was founded by Adolfo Carloni, Gianluca Maroncelli and Massimo Galavotti in 2012 and is headquartered in Sant'Angelo in Vado, Italy. | Directeur/Membre du Conseil | 15/03/2023 |
Anciens postes connus de Stephen D. Allen
| Sociétés | Poste | Fin |
|---|---|---|
Solexa Ltd.
 Solexa Ltd. Medical SpecialtiesHealth Technology Solexa Ltd. was a developer of instruments for analyzing genes in the process of drug development. It's research methods have included DNA sequencing, gene expression, genotyping and micro-RNA analysis to allow scientists to analyze individual genomes for drug development and personalized medicine. The company was headquartered in Saffron Walden, UK. | Directeur/Membre du Conseil | 30/01/2009 |
Direct Conversion AB
 Direct Conversion AB Medical SpecialtiesHealth Technology Direct Conversion AB manufactures and supplies X-Ray detectors such as cadmium telluride (CdTe) detectors. Its products include XC-THOR, XC-HYDRA, XC-TDI, XC-ACTAEON, SNAP 225, SNAP 150 and SNAP 100X2. The firm’s products are used in the dental, medical, welding, industrial, food and security industries. The company was founded in 1997 and is headquartered in Danderyd, Sweden. | Directeur/Membre du Conseil | 30/04/2008 |
Solexa, Inc.
 Solexa, Inc. Pharmaceuticals: OtherHealth Technology Solexa, Inc. used to create DNA cloning and analyses technologies to enhance gene discovery. It also used to provide genomics, genetics and proteomics technologies to assist the customers in the field of pharmaceutical and agriculture. The company was located in Hayward, CA. | Directeur/Membre du Conseil | 26/01/2007 |
| METTLER-TOLEDO INTERNATIONAL, INC. | Corporate Officer/Principal | 01/01/2004 |
| PE Corp. (New York) | Corporate Officer/Principal | 01/01/2000 |
Formation de Stephen D. Allen
| The University of Nottingham | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| METTLER-TOLEDO INTERNATIONAL, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Solexa, Inc.
Solexa, Inc. Pharmaceuticals: OtherHealth Technology Solexa, Inc. used to create DNA cloning and analyses technologies to enhance gene discovery. It also used to provide genomics, genetics and proteomics technologies to assist the customers in the field of pharmaceutical and agriculture. The company was located in Hayward, CA. | Health Technology |
Solexa Ltd.
Solexa Ltd. Medical SpecialtiesHealth Technology Solexa Ltd. was a developer of instruments for analyzing genes in the process of drug development. It's research methods have included DNA sequencing, gene expression, genotyping and micro-RNA analysis to allow scientists to analyze individual genomes for drug development and personalized medicine. The company was headquartered in Saffron Walden, UK. | Health Technology |
| PE Corp. (New York) | Health Technology |
Direct Conversion AB
Direct Conversion AB Medical SpecialtiesHealth Technology Direct Conversion AB manufactures and supplies X-Ray detectors such as cadmium telluride (CdTe) detectors. Its products include XC-THOR, XC-HYDRA, XC-TDI, XC-ACTAEON, SNAP 225, SNAP 150 and SNAP 100X2. The firm’s products are used in the dental, medical, welding, industrial, food and security industries. The company was founded in 1997 and is headquartered in Danderyd, Sweden. | Health Technology |
DNAe Group Holdings Ltd.
 DNAe Group Holdings Ltd. Medical SpecialtiesHealth Technology Part of Genting Bhd., DNAe Group Holdings Ltd. is a healthcare company based in London, UK. DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications, including infectious disease and cancer testing and monitoring. The British company is developing Lidia-seq™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians. DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The company's major shareholder is Genting Berhad, a Malaysian-based investor with a growing portfolio of investments in cutting-edge life sciences companies. The company was founded in 2003 by Christofer Toumazou. The CEO is Samuel Reed. | Health Technology |
NTP Nano Tech Projects SRL
NTP Nano Tech Projects SRL Miscellaneous Commercial ServicesCommercial Services NTP Nano Tech Projects SRL develops Nano-Eye, an advanced optical-laser microscopy device that can achieve optical resolutions below the micron size. The company was founded by Adolfo Carloni, Gianluca Maroncelli and Massimo Galavotti in 2012 and is headquartered in Sant'Angelo in Vado, Italy. | Commercial Services |
